Jonathan McNeill, See Remarks at Dyne Therapeutics, Inc. (DYN), sold 472 shares at $10.87 ($5K) on 2022-12-12, disclosed to the SEC on 2022-12-13.
Scheduled sale ($5k) by See Remarks under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| DYN | SELL | 2024-08-20 | $122K | — | Filing → |
| DYN | SELL | 2024-06-11 | $114K | — | Filing → |
| DYN | SELL | 2024-05-17 | $143K | — | Filing → |